Why I Would Buy Big Yellow Group plc, Finsbury Food Group plc And AstraZeneca plc

Royston Wild lays out the investment case for Big Yellow Group plc (LON: BYG), Finsbury Food Group plc (LON: FIF) and AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three Thursday headline makers that stock pickers should seriously consider.

Big Yellow Group

Storage house Big Yellow Group (LSE: BYG) greeted the market with yet another positive update in Thursday business, in turn pushing shares in the business 1.7% higher on the day. The Bagshot business saw like-for-like revenues leap 10% during April-June, to £20.7m, and its underlying occupancy rate jumped to 76.3% from 71.2% during the corresponding 2014 period.

And Big Yellow said that it expects this occupancy rate to leap another three to four percentage points during the current year, a projection I fully expect the firm to realise as Britons’ hoarding culture — boosted by improving spending power — fuels the need for extra space. This view is shared by the City, and earnings growth of 12% and 13% are pencilled in for the years concluding March 2016 and 2017 correspondingly.

Although Big Yellow sports slightly-elevated P/E ratios of 21.5 times and 19.2 times for these years, I expect these to continue collapsing in line with strong demand. And in my opinion projected dividends of 24.5p per share for 2016 and 27.6p for 2017 more than offsets these multiples, creating chunky yields of 3.8% and 4.2%.

Finsbury Food Group

Like Big Yellow, Finsbury Food Group (LSE: FIF) also cheered investors with a bubbly trading update during today’s session and was consequently dealing 6.3% higher. The stock has gained 54% since the turn of the year, propelling the business to current record highs of 92.5p per share at the current time. But I reckon further hefty gains can be expected.

Finsbury Foods announced that total sales jumped 45.8% during the 12 months concluding June 2015, helped by the recent acquisition of Fletchers. Consequently the specialty baker said it expects to exceed current profit expectations. So current City forecasts of a 10% earnings decline for the year could be set for a significant upgrade given today’s release, while predictions of a 27% increase in the current period could also receive a shot in the arm.

I believe that Finsbury Foods offers brilliant value for money, the caterer boasting an ultra-cheap earnings multiple of 9.8 for 2016 — any reading below 10 times is widely considered too good to pass on. When you factor in a projected dividend of 2.8p per share, too, producing a meaty 3.4% yield, I believe the food manufacturer is a hugely appetising stock pick.

AstraZeneca

Unlike its FTSE compatriots, however, AstraZeneca (LSE: AZN) was recently dealing 0.4% lower in Thursday’s session and this extends the broad downtrend seen during the past few months. However, I believe this current weakness — AstraZeneca has shed 11% since the middle of April — makes the business a bargain at the current time, even though the problem of exclusivity losses looks set to continue.

The number crunchers expect the London firm to arrest the heavy earnings declines of recent years in 2015 with a bottom-line stagnation, although a fresh 3% fall is predicted for 2016. But I am convinced AstraZeneca’s reinvigorated R&D pipeline — combined with surging healthcare demand from emerging regions — makes the business a terrific long-term growth pick. The business received FDA approval for its Iressa lung cancer drug just this week, and AstraZeneca plans to release a further six oncology-related products during the next five years alone.

I consider a prospective P/E multiple of 15.5 times decent value given these hot product prospects, while juicy dividend projections around 285 US cents for 2015 and 2016 cement the investment case in my opinion — these forecasts create a produce market-beating yield of 4.3%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »